Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Investigational new drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF02614216PMID 7499104
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging

  2004cited by this paper
• Acute and long-term nephrotoxicity of cis-platinum in man

  2004cited by this paper
• N-methylformamide-mediated enhancement of in vitro tumor cell chemosensitivity

  2004cited by this paper
• Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide

  2004cited by this paper
• Anguidine potentiates cis-platinum in human brain tumor cells

  2004cited by this paper
• Long-term prognosis of surgical patients with hepatocellular carcinoma

  2004cited by this paper
• Intracellular metabolites of cisplatin in the rat kidney

  2004cited by this paper
• The Statistical Analysis of Failure Time Data

  2003cited by this paper
• Potentiation of cisplatin antitumour activity by Ethyldeshydroxy-Sparsomycin in L1210 leukemia.

  1992cited by this paper
• L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice.

  1992cited by this paper
• Mechanism of action of sparsomycin in protein synthesis.

  1992cited by this paper
• Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth.

  1990cited by this paper
• Different interaction of cisplatin and etoposide on in vivo and in vitro tumor systems.

  1990cited by this paper
• Potentiation of cisplatin antitumor activity on L1210 leukemia s.c. by sparsomycin and three of its analogues.

  1989cited by this paper
• Infused L-histidinol and cisplatin: schedule, specificity, and proliferation dependence.

  1989cited by this paper
• Combination of N-methylformamide with cis-diamminedichloroplatinum (II) in murine mammary carcinoma: importance of timing.

  1989cited by this paper
• Lipophilic analogues of sparsomycin as strong inhibitors of protein synthesis and tumor growth: a structure-activity relationship study.

  1989cited by this paper
• L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia.

  1989cited by this paper
• In vivo antitumor activity of sparsomycin and its analogues in eight murine tumor models

  1988cited by this paper
• Synergistic cell inactivation of human NHIK 3025 cells by cinnamaldehyde in combination with cis-diamminedichloroplatinum(II).

  1988cited by this paper
• In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II).

  1988cited by this paper
• In vitro modulation of cisplatin cytotoxicity by sparsomycin inhibition of protein synthesis.

  1987cited by this paper
• Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.

  1987cited by this paper
• Structure-activity relationships of sparsomycin and its analogues. Inhibition of peptide bond formation in cell-free systems and of L1210 and bacterial cell growth.

  1987cited by this paper
• In vivo potentiation of cis-diamminedichloroplatinum (II) antitumor activity by pretreatment with sparsomycin.

  1986cited by this paper
• Fundamental studies with cisplatin.

  1985cited by this paper
• Charles F. Kettring prize. Fundamental studies with cisplatin

  1985cited by this paper
• Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology.

  1984cited by this paper
• Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology

  1984cited by this paper
• Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.

  1983cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents.

  1982cited by this paper
• Reduction of 1-beta-D-arabinofuranosylcytosine and adriamycin cytotoxicity following cell cycle arrest by anguidine.

  1981cited by this paper
• Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine.

  1981cited by this paper
• Effects of Cis-diamminedichloroplatinum (II) on hematopoietic stem cells in mice.

  1981cited by this paper
• Prevalent deficiency in tumor cells of cycloheximide-induced cycle arrest.

  1980cited by this paper
• The Statistical Analysis of Failure Time Data

  1980cited by this paper
• Antitumor activity of cis-dichlorodiammineplatinum(II).

  1979cited by this paper
• Design and evaluation of combination chemotherapy trials in experimental animal tumor systems.

  1979cited by this paper
• Selective inhibition of protein synthesis in virus-infected mammalian cells

  1979cited by this paper
• G1 phase chinese hamster V79-379A cells are inherently more sensitive to platinum bound to their DNA than mid S phase or asynchronously treated cells.

  1979cited by this paper
• Design and evaluation of combination chemotherapy trials in experimental animal tumor systems.

  1979cited by this paper
• Synergistic action of high‐dose hydroxyurea when used with cyglophosphamide and certain new organoplatinum complexes in treatment of advanced L1210 leukemia

  1978cited by this paper
• Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents.

  1977cited by this paper
• Cytotoxicity and Cell Cycle Specificity of Homoharringtonine

  1977cited by this paper
• The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.

  1973cited by this paper
• PROTOCOLS FOR SCREENING CHEMICAL AGENTS AND NATURAL PRODUCTS AGAINST ANIMAL TUMORS AND OTHER BIOLOGICAL SYSTEMS

  1972cited by this paper
• Mechanism of action of sparsomycin on protein synthesis.

  1970cited by this paper
• Sparsomycin inhibition of polypeptide synthesis promoted by synthetic and natural polynucleotides.

  1967cited by this paper
• Inhibition by sparsomycin and other antibiotics of the puromycin-induced release of polypeptide from ribosomes.

  1967cited by this paper
• Sparsomycin, an inhibitor of aminoacyl transfer to polypeptide.

  1966cited by this paper

• Natural products as drugs and tools for influencing core processes of eukaryotic mRNA translation.

  2021cites this paper
• Histological vis – a – vis biochemical assessment on the toxic level and antineoplastic efficacy of a synthetic drug Pt – ATP on experimental animal models

  2008cites this paper
• Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity.

  2000cites this paper
• Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in mice.

  1995cites this paper